Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
about
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancerToward rapamycin analog (rapalog)-based precision cancer therapyThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesCIViC databasePhase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responseDirect effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowAerobic Exercise and Pharmacological Treatments Counteract Cachexia by Modulating Autophagy in Colon CancerTumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyRecent and current Phase II clinical trials in endometrial cancer: review of the state of art.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).A phase Ib study of everolimus combined with metformin for patients with advanced cancer.Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies.Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.Effect and mechanism of inhibition of PI3K/Akt/mTOR signal pathway on chronic neuropathic pain and spinal microglia in a rat model of chronic constriction injuryMoving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.New therapies for advanced, recurrent, and metastatic endometrial cancers.Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
P2860
Q24185960-F6A6BEE1-17D7-44D4-90D0-F49C27122068Q26795606-E5884C8D-AC17-41FB-84E8-5B29730C16CEQ26851852-A3A25777-80B4-4A61-8271-E97B1FD32FADQ27612411-208791F3-14E3-454B-8DDB-9F4227F3CD74Q33422744-13503472-4673-488D-9C61-673FF935346BQ33675285-6A519FA7-EB8D-4844-83C3-4B45DDCA69AFQ36372293-07DF09CF-68E1-4CAB-AB2E-4C074AA07F74Q36731185-9D10ABC5-F1D8-4918-9A1B-05D81C3DA31AQ36950475-55320324-23F8-4E1E-87E3-EDF20F64D219Q37429034-60E2D9F5-6405-4BE3-9383-A645C657F990Q38203354-49B5397C-B0BB-4CFE-A19E-3CE2EA69D853Q38242086-4831144A-3A0C-4130-BE2E-078845A1FE97Q38388694-DD19FCAA-26C3-43BB-90E0-1AF71A0B4D6EQ38670844-8D50E145-558C-4B71-9474-8B97AB51DDAEQ38710557-86002849-CE59-4BF0-AE05-BE9A6E3C547EQ38753038-4DC8BD8A-F387-4D57-B088-4B8977668345Q39026772-A98386EC-EAF4-423B-8AA2-B128E7AA4D03Q41547803-36F221FF-2BC3-41B8-93D0-AA252D647836Q41592971-B76DD783-E602-4991-A904-A073F1D3C1E9Q45848384-7EBDA583-27A2-43B7-8578-1A456104F8C8Q47103210-003C9477-5719-413E-8291-A933FF31323AQ48005435-41B7E3C3-9CF4-443B-86A8-751E1007EBA2Q55018107-A22737AB-57A9-4A9F-AEFC-BF176B2BA84AQ57903637-D0FCD11C-1EF8-461F-8EC7-72D15FCAA040
P2860
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Molecular determinants of outc ...... ibition in endometrial cancer.
@ast
Molecular determinants of outc ...... ibition in endometrial cancer.
@en
Molecular determinants of outc ...... ibition in endometrial cancer.
@nl
type
label
Molecular determinants of outc ...... ibition in endometrial cancer.
@ast
Molecular determinants of outc ...... ibition in endometrial cancer.
@en
Molecular determinants of outc ...... ibition in endometrial cancer.
@nl
prefLabel
Molecular determinants of outc ...... ibition in endometrial cancer.
@ast
Molecular determinants of outc ...... ibition in endometrial cancer.
@en
Molecular determinants of outc ...... ibition in endometrial cancer.
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Molecular determinants of outc ...... ibition in endometrial cancer.
@en
P2093
Amit M Oza
Dongsheng Tu
Elizabeth A Eisenhauer
Helen J Mackay
Helga B Salvesen
Henrica M J Werner
Katherine Karakasis
P2860
P304
P356
10.1002/CNCR.28414
P407
P577
2014-02-15T00:00:00Z